JP4392991B2 - 免疫不全症の処置のための組成物、およびその調製と使用のための方法 - Google Patents

免疫不全症の処置のための組成物、およびその調製と使用のための方法 Download PDF

Info

Publication number
JP4392991B2
JP4392991B2 JP2000554761A JP2000554761A JP4392991B2 JP 4392991 B2 JP4392991 B2 JP 4392991B2 JP 2000554761 A JP2000554761 A JP 2000554761A JP 2000554761 A JP2000554761 A JP 2000554761A JP 4392991 B2 JP4392991 B2 JP 4392991B2
Authority
JP
Japan
Prior art keywords
afp
aap
reversible complex
complex
complex according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000554761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004500315A (ja
JP2004500315A5 (enExample
Inventor
オレグ・ストレルチェノク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardenia Investments Ltd
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Publication of JP2004500315A publication Critical patent/JP2004500315A/ja
Publication of JP2004500315A5 publication Critical patent/JP2004500315A5/ja
Application granted granted Critical
Publication of JP4392991B2 publication Critical patent/JP4392991B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000554761A 1998-06-17 1999-06-17 免疫不全症の処置のための組成物、およびその調製と使用のための方法 Expired - Fee Related JP4392991B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802162A SE9802162D0 (sv) 1998-06-17 1998-06-17 Immunostimulating composition
PCT/EP1999/004201 WO1999065936A2 (en) 1998-06-17 1999-06-17 Composition for the treatement of immune deficiencies and methods for its preparation and use

Publications (3)

Publication Number Publication Date
JP2004500315A JP2004500315A (ja) 2004-01-08
JP2004500315A5 JP2004500315A5 (enExample) 2006-08-03
JP4392991B2 true JP4392991B2 (ja) 2010-01-06

Family

ID=20411743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000554761A Expired - Fee Related JP4392991B2 (ja) 1998-06-17 1999-06-17 免疫不全症の処置のための組成物、およびその調製と使用のための方法

Country Status (10)

Country Link
US (1) US6599507B2 (enExample)
EP (1) EP1085909B1 (enExample)
JP (1) JP4392991B2 (enExample)
AT (1) ATE314094T1 (enExample)
AU (1) AU748838B2 (enExample)
BR (1) BR9911294B1 (enExample)
CA (1) CA2335079C (enExample)
DE (1) DE69929189T2 (enExample)
SE (1) SE9802162D0 (enExample)
WO (1) WO1999065936A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802162D0 (sv) 1998-06-17 1998-06-17 Nomet Management Services Bv Immunostimulating composition
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
ATE243701T1 (de) * 1999-03-16 2003-07-15 Ardenia Investments Ltd Polyungesättigte fettsäurederivate und deren verwendung in der krebsbehandlung
WO2002004467A1 (en) * 2000-07-12 2002-01-17 Ardenia Investments Ltd. Novel cytotoxic compounds and their use
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096863A (en) * 1996-08-23 2000-08-01 Regents Of The University Of Minnesota Self-assembling amphiphiles for construction of peptide secondary structures
SE9802162D0 (sv) 1998-06-17 1998-06-17 Nomet Management Services Bv Immunostimulating composition

Also Published As

Publication number Publication date
EP1085909A2 (en) 2001-03-28
EP1085909B1 (en) 2005-12-28
US6599507B2 (en) 2003-07-29
WO1999065936A3 (en) 2000-02-10
BR9911294B1 (pt) 2012-01-10
HK1035866A1 (en) 2001-12-14
BR9911294A (pt) 2002-01-02
AU748838B2 (en) 2002-06-13
SE9802162D0 (sv) 1998-06-17
JP2004500315A (ja) 2004-01-08
CA2335079A1 (en) 1999-12-23
WO1999065936A2 (en) 1999-12-23
AU4773499A (en) 2000-01-05
CA2335079C (en) 2008-01-08
DE69929189T2 (de) 2006-08-31
DE69929189D1 (de) 2006-02-02
ATE314094T1 (de) 2006-01-15
US20010034324A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
Kushner et al. Studies of acute phase protein: I. An Immunohistochemical method for the localization of cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions
US4980462A (en) Antiviral agents
US4298590A (en) Detection of malignant tumor cells
Marcus et al. Localization of glycosphingolipids in human tissues by immunofluorescence
CA2215339C (en) Immunomodulating compositions from bile for the treatment of immune system disorders
CN118203658A (zh) 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法
JP4392991B2 (ja) 免疫不全症の処置のための組成物、およびその調製と使用のための方法
Gibbons et al. Studies in immunochemistry. 14. The isolation and properties of substances of human origin possessing blood-group B specificity
US4624932A (en) Recognins and their chemoreciprocals
Bodenheimer Jr et al. Characterization of a new monoclonal antibody to rat macrophages and Kupffer cells
RU2205010C2 (ru) Природные противоопухолевые или противовирусные вещества и их применение
EP0007214A1 (en) Product for detecting the presence of cancerous or malignant tumor cells
Birgens The monocytic receptor for lactoferrin and its involvement in lactoferrin-mediated iron transport
Irimura et al. Glycoprotein profiles of macrophages at different stages of activation as revealed by lectin binding after electrophoretic separation
Susz et al. The affinity of the fucose‐binding lectin from Lotus tetragonolobus for glycopeptides and oligosaccharides accumulating in fucosidosis
Yamashita et al. Intestinal absorption and urinary excretion of antitumor peptidomannan KS-2 after oral administration in rats
HK1035866B (en) A complex of alpha-fetoprotein (afp) and a polyunsaturated fatty acid derivative for the treatment of immune deficiencies
US4976957A (en) Process for the production of recognins and their chemoreciprocals
MXPA00012558A (en) Composition for the treatement of immune deficiencies and methods for its preparation and use
WO2020113232A1 (en) Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteins
EP0015755A2 (en) Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors
Fletcher et al. Biochemical and morphological properties of bovine erythrocyte membrane glycoproteins
JPS6028934A (ja) 細胞分化誘導物質
KR20020084833A (ko) 한국산 해양 밤게로부터 추출된 렉틴 단백질, 그의제조방법 및 용도
Burtin et al. Characterization of the nonspecific cross-reacting antigen (NCA) in human monocytes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090924

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091013

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121023

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121023

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131023

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees